vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.
AGIOS PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($20.0M vs $19.6M, roughly 1.0× STANDARD BIOTOOLS INC.). STANDARD BIOTOOLS INC. runs the higher net margin — -177.4% vs -541.1%, a 363.7% gap on every dollar of revenue. On growth, AGIOS PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (86.1% vs -11.5%). STANDARD BIOTOOLS INC. produced more free cash flow last quarter ($-23.1M vs $-97.3M). Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs -12.2%).
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.
AGIO vs LAB — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $19.6M |
| Net Profit | $-108.0M | $-34.7M |
| Gross Margin | 90.6% | 48.5% |
| Operating Margin | -608.9% | -168.5% |
| Net Margin | -541.1% | -177.4% |
| Revenue YoY | 86.1% | -11.5% |
| Net Profit YoY | -11.9% | -28.8% |
| EPS (diluted) | $-1.86 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.0M | — | ||
| Q3 25 | $12.9M | $19.6M | ||
| Q2 25 | $12.5M | $21.8M | ||
| Q1 25 | $8.7M | $40.8M | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $9.0M | $22.1M | ||
| Q2 24 | $8.6M | $22.5M | ||
| Q1 24 | $8.2M | $45.5M |
| Q4 25 | $-108.0M | — | ||
| Q3 25 | $-103.4M | $-34.7M | ||
| Q2 25 | $-112.0M | $-33.5M | ||
| Q1 25 | $-89.3M | $-26.0M | ||
| Q4 24 | $-96.5M | — | ||
| Q3 24 | $947.9M | $-26.9M | ||
| Q2 24 | $-96.1M | $-45.7M | ||
| Q1 24 | $-81.5M | $-32.2M |
| Q4 25 | 90.6% | — | ||
| Q3 25 | 87.0% | 48.5% | ||
| Q2 25 | 86.3% | 48.8% | ||
| Q1 25 | 87.6% | 48.4% | ||
| Q4 24 | 88.3% | — | ||
| Q3 24 | 91.3% | 54.9% | ||
| Q2 24 | 82.6% | 46.1% | ||
| Q1 24 | 92.3% | 53.1% |
| Q4 25 | -608.9% | — | ||
| Q3 25 | -907.4% | -168.5% | ||
| Q2 25 | -1020.1% | -118.1% | ||
| Q1 25 | -1222.0% | -80.8% | ||
| Q4 24 | -1165.3% | — | ||
| Q3 24 | -1146.9% | -120.9% | ||
| Q2 24 | -1228.3% | -134.5% | ||
| Q1 24 | -1124.3% | -132.2% |
| Q4 25 | -541.1% | — | ||
| Q3 25 | -803.1% | -177.4% | ||
| Q2 25 | -899.4% | -153.7% | ||
| Q1 25 | -1023.3% | -63.8% | ||
| Q4 24 | -899.6% | — | ||
| Q3 24 | 10574.7% | -122.0% | ||
| Q2 24 | -1115.7% | -203.3% | ||
| Q1 24 | -995.8% | -70.6% |
| Q4 25 | $-1.86 | — | ||
| Q3 25 | $-1.78 | $-0.09 | ||
| Q2 25 | $-1.93 | $-0.09 | ||
| Q1 25 | $-1.55 | $-0.07 | ||
| Q4 24 | $-1.44 | — | ||
| Q3 24 | $16.22 | $-0.07 | ||
| Q2 24 | $-1.69 | $-0.12 | ||
| Q1 24 | $-1.45 | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | $129.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $399.7M |
| Total Assets | $1.3B | $539.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.1M | — | ||
| Q3 25 | $92.7M | $129.4M | ||
| Q2 25 | $80.9M | $158.6M | ||
| Q1 25 | $79.0M | $150.9M | ||
| Q4 24 | $76.2M | — | ||
| Q3 24 | $253.7M | $210.6M | ||
| Q2 24 | $84.5M | $269.8M | ||
| Q1 24 | $118.8M | $287.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.3B | $399.7M | ||
| Q2 25 | $1.4B | $424.5M | ||
| Q1 25 | $1.5B | $454.6M | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.6B | $489.3M | ||
| Q2 24 | $660.5M | $510.3M | ||
| Q1 24 | $743.9M | $577.3M |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.4B | $539.6M | ||
| Q2 25 | $1.5B | $557.0M | ||
| Q1 25 | $1.6B | $579.6M | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.8B | $681.5M | ||
| Q2 24 | $773.1M | $708.7M | ||
| Q1 24 | $849.7M | $777.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | $-22.2M |
| Free Cash FlowOCF − Capex | $-97.3M | $-23.1M |
| FCF MarginFCF / Revenue | -487.5% | -118.1% |
| Capex IntensityCapex / Revenue | 5.6% | 4.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | $-111.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-96.2M | — | ||
| Q3 25 | $-88.2M | $-22.2M | ||
| Q2 25 | $-77.1M | $-20.7M | ||
| Q1 25 | $-111.5M | $-30.3M | ||
| Q4 24 | $-133.2M | — | ||
| Q3 24 | $-84.2M | $-27.9M | ||
| Q2 24 | $-72.6M | $-39.0M | ||
| Q1 24 | $-99.9M | $-62.5M |
| Q4 25 | $-97.3M | — | ||
| Q3 25 | $-89.7M | $-23.1M | ||
| Q2 25 | $-78.0M | $-22.6M | ||
| Q1 25 | $-112.3M | $-35.3M | ||
| Q4 24 | $-134.1M | — | ||
| Q3 24 | $-84.6M | $-30.1M | ||
| Q2 24 | $-72.7M | $-41.0M | ||
| Q1 24 | $-100.0M | $-63.3M |
| Q4 25 | -487.5% | — | ||
| Q3 25 | -696.5% | -118.1% | ||
| Q2 25 | -626.2% | -103.6% | ||
| Q1 25 | -1286.4% | -86.6% | ||
| Q4 24 | -1250.1% | — | ||
| Q3 24 | -944.2% | -136.4% | ||
| Q2 24 | -844.4% | -182.2% | ||
| Q1 24 | -1221.2% | -138.9% |
| Q4 25 | 5.6% | — | ||
| Q3 25 | 12.1% | 4.5% | ||
| Q2 25 | 7.0% | 8.7% | ||
| Q1 25 | 8.8% | 12.4% | ||
| Q4 24 | 9.0% | — | ||
| Q3 24 | 4.7% | 10.2% | ||
| Q2 24 | 1.8% | 8.6% | ||
| Q1 24 | 1.7% | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.09× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGIO
Segment breakdown not available.
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
